NCT05200104View on ClinicalTrials.gov

Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
ALD (Adrenoleukodystrophy)
Interventions
DRUG

PXL065

PXL065 22.5 mg QD

Sponsors

Lead Sponsor

Poxel SA
All Listed Sponsors
lead

Poxel SA

INDUSTRY

NCT05200104 - Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | Biotech Hunter | Biotech Hunter